within Pharmacolibrary.Drugs.ATC.L;

model L01DB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 42.2 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,
    adminCount     = 1,
    Vd             = 0.048600000000000004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Epirubicin is an anthracycline antineoplastic agent used primarily in the treatment of breast cancer. It works as a DNA synthesis inhibitor, intercalating into DNA and inhibiting topoisomerase II. Epirubicin is approved for use in multiple countries for the treatment of breast cancer and is sometimes used in other solid tumors as part of combination chemotherapy regimens.</p><h4>Pharmacokinetics</h4><p>Adult cancer patients, both sexes, typical intravenous administration as part of chemotherapy, based on population PK analyses.</p><h4>References</h4><ol><li><p>Ismael, G, et al., &amp; Jackisch, C (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. <i>The Lancet. Oncology</i> 13(9) 869–878. DOI:<a href=&quot;https://doi.org/10.1016/S1470-2045(12)70329-7&quot;>10.1016/S1470-2045(12)70329-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22884505/&quot;>https://pubmed.ncbi.nlm.nih.gov/22884505</a></p></li><li><p>Eksborg, S (1989). Pharmacokinetics of anthracyclines. <i>Acta oncologica (Stockholm, Sweden)</i> 28(6) 873–876. DOI:<a href=&quot;https://doi.org/10.3109/02841868909092323&quot;>10.3109/02841868909092323</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2611038/&quot;>https://pubmed.ncbi.nlm.nih.gov/2611038</a></p></li><li><p>Dine, T, et al., &amp; Cazin, M (1991). Pharmacokinetics of epirubicin after intravenous administration: experimental and clinical aspects. <i>Methods and findings in experimental and clinical pharmacology</i> 13(7) 483–489. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1784146/&quot;>https://pubmed.ncbi.nlm.nih.gov/1784146</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01DB03;
